Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10008852HBVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS30003207HIVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS30003208HIVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS30051895HIVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS30051896HIVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS30051897HIVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS20054320HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS20029523HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS20030522HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TVIS20029524HPVENSG00000115232.14protein_codingITGA4NoNo3676P13612
TCGA Plot Options
Drug Information
GeneITGA4
DrugBank IDDB09033
Drug NameVedolizumab
Target IDBE0000590
UniProt IDP13612
Regulation Typeantibody
PubMed IDs19509315
CitationsSoler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER: The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. doi: 10.1124/jpet.109.153973. Epub 2009 Jun 9.
GroupsApproved
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBLCHEMBL1743087